Why carry out this study?

Non-alcoholic fatty liver disease (NAFLD) represents a disease spectrum ranging from simple steatosis to steatohepatitis (NASH), fibrosis, and cirrhosis and is frequently associated to metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM).

Neo-Policaptil Gel Retard (PGR), a natural phytocomplex, has been demonstrated to be effective in reducing factors associated with MS and T2DM, such as blood sugar, cholesterol, triglycerides, and abdominal fat distribution, all factors involved in MS and T2DM and strongly linked to fat accumulation in the liver.

Some non-invasive and validated indicators of steatosis and liver fibrosis, such as Fatty Liver Index (FLI), Fibrosis (FIB)-4 Score (FIB-4), and NAFLD Fibrosis Score (NFS), have long been used to identify and quantify their extent.

What was learned from the study?

This article documents for the first time how the use of PGR in subjects with fatty liver, MS, and T2DM is able to significantly reduce the number of subjects with and the entity of liver steatosis and fibrosis and to reduce the level of transaminases.

The use of PGR represents a new possible therapeutic option in subjects with MS and T2DM complicated by high at liver, as in metabolic NAFLD (MAFLD).